Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Roth Upgrades Ceradyne to Buy


Roth Capital upgraded Ceradyne (CRDN) to buy from hold.

Analyst Steven Gish says the House recently passed the fiscal 2005 (Sep.) National Defense Authorization Act, allocating over $400 million for body armor. He says Ceradyne stands to benefit directly from this funding as it's one of leading providers of small arms protective inserts.

Gish notes new contracts could come down this summer, which would also bode well for the company. In addition, he thinks that Ceradyne's recent acquisition of Quest Technology could benefit its orthopedic segment in the long run. He raised the $1.22 2004 EPS estimate to $1.27, and upped the $1.35 2005 estimate to $1.44. He has a $38 target.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus